Price to FCFE (P/FCFE)
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Net Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Free Cash Flow to Equity (FCFE)
Abbott Laboratories, FCFE calculation
US$ in millions
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Net Cash from Operating Activities
- There was a significant increase in net cash from operating activities from 2020 to 2021, rising from 7,901 million to 10,533 million US dollars. However, in 2022, this metric decreased slightly to 9,581 million, followed by a more pronounced decline to 7,261 million in 2023. In 2024, the net cash from operating activities recovered partially to 8,558 million. Overall, the trend indicates fluctuation with a peak in 2021 and a notable dip in 2023 before some recovery.
- Free Cash Flow to Equity (FCFE)
- Free cash flow to equity showed a notable increase from 5,674 million in 2020 to 8,400 million in 2021. Subsequently, FCFE decreased to 7,105 million in 2022, and experienced a sharp decline to 2,584 million in 2023. By 2024, FCFE rebounded to 5,814 million. This pattern reveals considerable volatility with a substantial drop in 2023, followed by a significant partial recovery in the following year.
- Comparative Insights
- Both net cash from operating activities and free cash flow to equity peaked in 2021, followed by declines in the subsequent years, with the most pronounced drop occurring in 2023. This suggests possible operational challenges or increased capital expenditures impacting cash flows during that period. The recovery observed in 2024 in both metrics indicates a potential stabilization or improvement in operational efficiency or capital management.
Price to FCFE Ratio, Current
Abbott Laboratories, current P/FCFE calculation, comparison to benchmarks
| No. shares of common stock outstanding | |
| Selected Financial Data (US$) | |
| Free cash flow to equity (FCFE) (in millions) | |
| FCFE per share | |
| Current share price (P) | |
| Valuation Ratio | |
| P/FCFE | |
| Benchmarks | |
| P/FCFE, Competitors1 | |
| CVS Health Corp. | |
| Elevance Health Inc. | |
| Intuitive Surgical Inc. | |
| Medtronic PLC | |
| UnitedHealth Group Inc. | |
| P/FCFE, Sector | |
| Health Care Equipment & Services | |
| P/FCFE, Industry | |
| Health Care | |
Based on: 10-K (reporting date: 2024-12-31).
1 Click competitor name to see calculations.
If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.
Price to FCFE Ratio, Historical
Abbott Laboratories, historical P/FCFE calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | ||||||
| Selected Financial Data (US$) | ||||||
| Free cash flow to equity (FCFE) (in millions)2 | ||||||
| FCFE per share3 | ||||||
| Share price1, 4 | ||||||
| Valuation Ratio | ||||||
| P/FCFE5 | ||||||
| Benchmarks | ||||||
| P/FCFE, Competitors6 | ||||||
| CVS Health Corp. | ||||||
| Elevance Health Inc. | ||||||
| Intuitive Surgical Inc. | ||||||
| Medtronic PLC | ||||||
| UnitedHealth Group Inc. | ||||||
| P/FCFE, Sector | ||||||
| Health Care Equipment & Services | ||||||
| P/FCFE, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Data adjusted for splits and stock dividends.
3 2024 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= ÷ =
4 Closing price as at the filing date of Abbott Laboratories Annual Report.
5 2024 Calculation
P/FCFE = Share price ÷ FCFE per share
= ÷ =
6 Click competitor name to see calculations.
- Share Price
- The share price exhibited fluctuations over the five-year period. It started at $123.04 in 2020, declined steadily to a low of $106.74 in 2022, then recovered to $114.01 in 2023, and increased significantly to $134.92 in 2024. This indicates an overall upward trend in the share price from 2022 onwards, with the highest value recorded in 2024.
- FCFE per Share
- The free cash flow to equity (FCFE) per share showed variability across the years. It rose from $3.20 in 2020 to a peak of $4.76 in 2021, then decreased to $4.09 in 2022, followed by a notable decline to $1.49 in 2023. In 2024, FCFE per share partially recovered to $3.35. This pattern reflects fluctuating free cash flow generation, with a significant dip in 2023.
- P/FCFE Ratio
- The price-to-FCFE ratio demonstrated considerable volatility. It started high at 38.42 in 2020, dropped to around the mid-20s range in 2021 and 2022 (24.52 and 26.11 respectively), then surged dramatically to 76.56 in 2023 before decreasing to 40.25 in 2024. The spike in 2023 aligns with the sharp decline in FCFE per share, suggesting price valuation temporarily outpaced free cash flow generation.
- Summary
- Overall, the share price recovered and surpassed early period values by 2024, despite significant fluctuations in FCFE per share. The sharp decline in FCFE per share in 2023 caused an inflated P/FCFE ratio, indicating potentially overvalued shares relative to free cash flow that year. The partial rebound in FCFE per share in 2024 corresponded with a normalization of the P/FCFE ratio, though it remained elevated compared to earlier years. These trends suggest variable free cash flow performance affected valuation metrics, while the share price showed resilience and growth.